Impact of Virologic Breakthrough and HBIG Regimen on Hepatitis B Recurrence After Liver Transplantation (pages 1823–1833)
B. Degertekin, Steven-Huy B. Han, E. B. Keeffe, E. R. Schiff, V. A. Luketic, R. S. Brown, Jr., S. Emre, C. Soldevila-Pico, K. R. Reddy, M. B. Ishitani, T. T. Tran, T. L. Pruett, A. S. F. Lok and the NIH HBV-OLT Study Group
Article first published online: 23 MAR 2010 | DOI: 10.1111/j.1600-6143.2010.03046.x
In 183 liver transplants for hepatitis B, low dose or finite duration of HBIG when combined with antiviral therapy resulted in low rates of HBV recurrence after liver transplantation, including patients with breakthrough pretransplant, as long as rescue therapy is administered pre- and post-transplant. See Editorial by Gane on page 1721.